Recent Quotes (30 days)

You have no recent quotes
chg | %

AstraZeneca plc news

   Watch this stock
Showing stories 1 - 10 of about 160   

Articles published

AZN 5,209.78 +24.78 (0.48%)
price chart
AstraZeneca PLC (AZN): Strong Industry, Solid Earnings Estimate Revisions
One stock that might be an intriguing choice for investors right now is AstraZeneca PLC AZN . This is because this security in the Large Cap Pharmaceuticals space is seeing solid earnings estimate revision activity, and is in great company from a Zacks ...
AstraZeneca PLC 'one for the brave', but still a 'buy', according to leading ...
One for the brave, yes, certainly, but drugs giant AstraZeneca PLC (LON:AZN) is still a 'buy', according to City broker Liberum, which nudged up its price target following some key data and a sharp rise in the share price.
GlaxoSmithKline versus AstraZeneca: which share price will rise the fastest?  Investomania (blog)
AstraZeneca plc (AZN) Given Average Recommendation of "Hold" by ...  The Cerbat Gem
AstraZeneca reports “highly encouraging” initial results from its PACIFIC lung ...
It may not be the trial that AstraZeneca PLC (LON:AZN, NYSE:AZN) investors are pinning their hopes on, but the big pharma group has already achieved some success in the lung cancer space after revealing “positive results” for its Phase III PACIFIC trial.
AstraZeneca plans Imfinzi submission after trial  MarketWatch
AstraZeneca plc (ADR) (AZN) Shares Soar on Lung Cancer Drug Success
Lung cancer success means AstraZeneca now has a “significant lead” over ...
AstraZeneca was famously late to the PD-1/ PD-L1 scene - a class of proteins that scientists think could suppress the immune system during events such as cancer - but Deutsche Bank thinks last week's news now gives its immuno-oncology franchise a ...
AstraZeneca Imfinzi Positive in Phase III Lung Cancer Study  Nasdaq
AstraZeneca PLC (NYSE:AZN)'s durvalumab show reduction in risk of death ...  Benchmark Monitor
AstraZeneca, Merck and Bristol-Myers vying for dominance in lung cancer market
Merck's success has come at the expense of both AstraZeneca and Bristol-Myers and it's certainly in pole position at the moment, but the race to be the long-term undisputed leader in the market is far from over.
Merck Keytruda Combination Approval Good News, But How Good?  BloombergQuint
AstraZeneca Sues Executive After Rival Glaxo Lures Him Away
AstraZeneca Plc filed a lawsuit in a London court against former executive Luke Miels saying he's in violation of his employment agreement, four months after rival drugmaker GlaxoSmithKline Plc announced it was poaching him to run its largest business.
AstraZeneca PLC (AZN) to Sell Rights to Metoprolol Based Treatments in Europe ...
Recordati announced that it has entered into an agreement with AstraZeneca (NYSE: AZN) for the acquisition of the rights to Seloken�/Seloken� ZOK (metoprolol succinate) and associated Logimax� fixed dose combination (metoprolol succinate and ...
AstraZeneca, Recordati Enter Deal For Seloken; AstraZeneca To Receive $300 Mln  Nasdaq
AstraZeneca, Recordati agree Seloken rights deal  MarketWatch
AstraZeneca: No CV reduction in Bydureon trial
LONDON--Pharmaceutical giant AstraZeneca PLC AZN, +0.28% said Tuesday that a recent trial of Bydureon met the primary safety objectives to not increase cardiovascular risk for patients with Type-2 diabetes.
AstraZeneca Shareholders Revolt Against Drug Giant's Pay Report
AstraZeneca Plc suffered one of the largest shareholder rebellions so far this year in the U.K., with 39 percent voting against the drug giant's pay report.
AstraZeneca Plc's (AZN) CEO Pascal Soriot on Q1 2017 Results - Earnings ...  Seeking Alpha
AstraZeneca profit down as sales for key drug fall  MarketWatch
AstraZeneca plc (AZN) Price Target Cut to GBX 4900
AstraZeneca plc logo AstraZeneca plc (LON:AZN) had its target price reduced by Jefferies Group LLC from GBX 5,050 ($65.70) to GBX 4,900 ($63.74) in a research note published on Friday, April 21st.
AstraZeneca plc (AZN) Given "Buy" Rating at Morgan Stanley  Sports Perspectives
AstraZeneca PLC added 0.56% in its Stock Price in the Previous Trading Session  Free Observer